Twist Bioscience Corporation: Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Twist Bioscience Corporation: Twist Bioscience and Vivlion Partner to Generate gRNA Libraries for CRISPR Applications
Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Vivlion GmbH, a company providing next-generation CRISPR gRNA libraries and screening services for the global R&D market, today announced a collaboration for the generation of gRNA libraries for CRISPR applications. CRISPR\Cas is a powerful functional genomics tool used for a wide range of applications including genome engineering and target discovery for drug development. Research using CRISPR continues to accelerate into many different areas. This collaboration combines Twist s ability to generate highly uniform long oligos at scale with Vivlion s ability to translate these into equally highly uniform CRISPR libraries for the next generation of high-throughput CRISPR screenings, said Emily M. Lep
Posted on 323
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of the Twist NGS Methylation Detection System, a robust, end-to-end sample preparation and target enrichment solution for identifying methylated regions in the human genome.
DNA methylation plays a key role in many biological processes including cancer. When present on a single nucleotide, a methyl group can alter genetic behavior without changing the DNA sequence. Analyzing these methylation patterns provides unique understanding of disease pathology, including the ability to screen for cancer earlier using blood samples known as “liquid biopsies.”
Twist Bioscience Corporation: Twist Bioscience to Offer Synthetic RNA Control for UK Variant Strain of SARS-CoV-2 Controls to be Used to Develop, Verify and Validate Tests that Identify More Transmissible Variant
Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced plans to offer a new synthetic RNA control that includes the new variant of SARS-CoV-2 circulating in the United Kingdom and South Africa. This new variant strain of SARS-CoV-2 contains multiple spike protein mutations as well as mutations in other areas of the viral genome.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Twist Bioscience to Offer Synthetic RNA Control for UK Variant Strain of SARS-CoV-2
December 23, 2020 GMT
SOUTH SAN FRANCISCO, Calif. (BUSINESS WIRE) Dec 23, 2020
Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced plans to offer a new synthetic RNA control that includes the new variant of SARS-CoV-2 circulating in the United Kingdom and South Africa. This new variant strain of SARS-CoV-2 contains multiple spike protein mutations as well as mutations in other areas of the viral genome.